Thalidomide and dexamethasone for resistant multiple myeloma

被引：146

作者：

Anagnostopoulos, A ^{[1
]}

Weber, D ^{[1
]}

Rankin, K ^{[1
]}

Delasalle, K ^{[1
]}

Alexanian, R ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2003年 / 121卷 / 05期

关键词：

multiple myeloma; thalidomide; dexamethasone;

D O I：

10.1046/j.1365-2141.2003.04345.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high-dose dexamethasone-based therapies. Remission was observed in 22 patients (47%), including six patients with complete remission. Side-effects were frequent, mild and usually reversible, but deep vein thrombosis occurred in 8% of patients. Survival and remission times were longer among patients treated for previous resistant disease rather than for resistant relapse. This experience supports the use of thalidomide-dexamethasone in myeloma patients with resistant disease and justifies further trials in newly diagnosed patients.

引用

页码：768 / 771

页数：4

共 12 条

[1]

Alexanian R, 2002, BLOOD, V100, p180A

[2] EARLY MYELOABLATIVE THERAPY FOR MULTIPLE-MYELOMA [J].

ALEXANIAN, R ;

DIMOPOULOS, MA ;

HESTER, J ;

DELASALLE, K ;

CHAMPLIN, R .

BLOOD, 1994, 84 (12) :4278-4282

[3]

ALEXANIAN R, 1992, BLOOD, V80, P887

[4] Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma [J].

Alexanian, R ;

Weber, D ;

Giralt, S ;

Dimopoulos, M ;

Delasalle, K ;

Smith, T ;

Champlin, R .

BONE MARROW TRANSPLANTATION, 2001, 27 (10) :1037-1043

[5] ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].

ANDERSON, JR ;

CAIN, KC ;

GELBER, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719

[6] Thalidomide and dexamethasone combination for refractory multiple myeloma [J].

Dimopoulos, MA ;

Zervas, K ;

Kouvatseas, G ;

Galani, E ;

Grigoraki, V ;

Kiamouris, C ;

Vervessou, E ;

Samantas, E ;

Papadimitriou, C ;

Economou, O ;

Gika, D ;

Panayiotidis, P ;

Christakis, I ;

Anagnostopoulos, N .

ANNALS OF ONCOLOGY, 2001, 12 (07) :991-995

[7] Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].

Hideshima, T ;

Chauhan, D ;

Shima, Y ;

Raje, N ;

Davies, FE ;

Tai, YT ;

Treon, SP ;

Lin, B ;

Schlossman, RL ;

Richardson, P ;

Muller, G ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2000, 96 (09) :2943-2950

[8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[9] DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS REQUIRING PROLONGED OBSERVATION OF EACH PATIENT .2. ANALYSIS AND EXAMPLES [J].

PETO, R ;

PIKE, MC ;

ARMITAGE, P ;

BRESLOW, NE ;

COX, DR ;

HOWARD, SV ;

MANTEL, N ;

MCPHERSON, K ;

PETO, J ;

SMITH, PG .

BRITISH JOURNAL OF CANCER, 1977, 35 (01) :1-39

[10] Thalidomide in the treatment of relapsed multiple myeloma [J].

Rajkumar, SV ;

Fonseca, R ;

Dispenzieri, A ;

Lacy, MQ ;

Lust, JA ;

Witzig, TE ;

Kyle, RA ;

Gertz, MA ;

Greipp, PR .

MAYO CLINIC PROCEEDINGS, 2000, 75 (09) :897-901

← 1 2 →